TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7047649
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (no antibiotic)
Study: 22583135
Drug: Drug provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug provocation test (DPT)
Study: 11908467
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg once daily for 8 weeks
Study: 10456811
Drug: Metoclopramid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramid (10 mg i.v. bolus during dopamine infusion)
Study: 8834935
Drug: Zolpidem 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 15 mg
Study: 2475056
Drug: Intramuscular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular therapy with vitamin D (600,000 IU)
Study: 19143855
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg once daily (qd)
Study: 19143855
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily (bid)
Study: 17166990
Drug: Fixed-dose budesonide
Normalized name: budesonide Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose budesonide (320 microg qd)
Study: 17166990
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (budesonide/formoterol 80/4.5 microg qd)
Study: 10809032
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once daily intravenously followed by 500 mg once daily orally)
Study: 10809032
Drug: Cefuroxime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime plus erythromycin (750 mg every 8 hours intravenously followed by 500 mg twice daily orally for cefuroxime and 500-1000 mg every 6 hours for erythromycin)
Study: 28974835
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy with bone replacement material (group 2)
Study: 28974835
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy without bone replacement material (group 1)
Study: 1592346
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (600 mg/day)
Study: 1968871
Drug: Taurine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (1.5 g/day)
Study: 367885
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day cimetidine
Study: 367885
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g and 2 g)
Study: 31692851
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg once daily for 4 weeks
Study: 28733799
Drug: Incredible Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incredible Years Parents, Babies and Toddlers program with depression psychoeducation (12 weekly sessions)
Study: 23508626
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm of a randomized treatment sequence
Study: 15605645
Drug: Citriodiol spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citriodiol spray applied daily for 2 weeks to the lower extremities
Study: 30300378
Drug: Intermanual transfer
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermanual transfer training program with mirror therapy and motor imagery
Study: 26610333
Drug: 600 mcg
Normalized name: Biotin 600 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg of misoprostol administered after birth when oxytocin was not available
Study: 24055414
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg orally once daily on days 1-14) in combination with bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Study: 17712060
Drug: Turkey cutlets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turkey cutlets soaked in red wine prior to heating plus 200 ml of red wine (C)
Study: 7518480
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of substance P (11.2 pmol/min) plus adenosine (125 to 2000 micrograms/min) during intrailiac infusion
Study: 7518480
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of substance P (11.2 pmol/min) plus adenosine (50 to 800 micrograms/min) during intracoronary infusion
Study: 7518480
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (125 to 2000 micrograms/min) during intrailiac infusion
Study: 7518480
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (50 to 800 micrograms/min) during intracoronary infusion
Study: 3290870
Drug: High-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose regimen (1,650 mg/day)
Study: 3290870
Drug: Low-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose regimen (day 1, 1,100 mg; day 2, 825 mg)
Study: 27175706
Drug: SVV-guided fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVV-guided fluid therapy (SVV maintained at 10%-20%)
Study: 20881072
Drug: Phylloquinone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone (1 mg daily for 12 months)
Study: 9758075
Drug: No-acupuncture control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-acupuncture control (nonsteroidal anti-inflammatory medication)
Study: 7838418
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen plus cetyltrimethylammonium naproxenate douches
Study: 3045545
Drug: Corticosteroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids for 10 weeks plus daily azathioprine for one year
Study: 3045545
Drug: No immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunosuppressive therapy (Control)
Study: 9499664
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) and cytosine arabinoside (Ara‐C) induction therapy for patients < 65 years: Ara‐C 1 g/m2/day i.v. 6‐hour infusion on days 1‐4, IDA 10 mg/m2/day i.v. on days 1‐3.
Study: 9499664
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) and cytosine arabinoside (Ara‐C) induction therapy for elderly patients (>= 65 years): Ara‐C 1 g/m2/day 6 hours infusion on days 1 and 2, IDA 10 mg/m2/day i.v. on days 1 and 2.
Study: 10464875
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol
Study: 10342550
Drug: Oral albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral albuterol
Study: 31509210
Drug: Text-messaging program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-messaging program (MyTeen) for parents, 1 daily text message over 4 weeks
Study: 29909907
Drug: Cixutumumab (CIX)
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (CIX) 10 mg/kg with Cetuximab (CET) 500 mg/m2 every 2 weeks
Study: 25222385
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) plus home exercise and advice (HEA) for 12 weeks
Study: 14657819
Drug: Heparin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (0.5 IU/mL)
Study: 10639376
Drug: Cyclodextrin solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclodextrin solution of itraconazole
Study: 8799519
Drug: Intravenous fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluticasone propionate (FP)
Study: 31540616
Drug: Employed at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Employed at end-of-treatment
Study: 31540616
Drug: Unemployed at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unemployed at baseline and acquired employment by end-of-treatment
Study: 31540616
Drug: Unemployed at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unemployed at baseline and remained unemployed by end-of-treatment
Study: 29113548
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg + Solifenacin 10 mg per day (Group A, N = 93)
Study: 29113548
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg + Solifenacin 20 mg (Group B, N = 83)
Study: 29113548
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg + Placebo (Control Group C, N = 86)
Study: 26898348
Drug: SFC DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SFC DPI (50/250 μg twice daily)
Study: 26898348
Drug: SFC pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC pMDI (four puffs of 25/125 μg daily)
Study: 17148567
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate with 135.5 mg isoflavones
Study: 12370800
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate and 500 mg calcium daily (n = 8)
Study: 12370800
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium daily (n = 11)
Study: 27370231
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control
Study: 2655606
Drug: Chlorambucil (0.05‐0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.05‐0.1 mg/kg/day)
Study: 773494
Drug: Atenolol (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (three different doses taken once daily for four weeks)
Study: 27471824
Drug: Standard vitreous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vitreous tap and injection technique
Study: 26079405
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (pravastatin) initiated in childhood, duration 10 years
Study: 19070418
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus alpha‐blocker
Study: 16796706
Drug: Itraconazole administered
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole administered orally for 6 days, with fexofenadine on days 1, 3, and 6.
Study: 16796706
Drug: Fexofenadine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine administered alone.
Study: 1551743
Drug: 15(s) 15
Normalized name: Quaternium 15
DrugBank: Quaternium-15 (DB14198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(s) 15 Me PGF2 alpha intravesical instillation (1 mg daily for a maximum of 5 days)
Study: 3553479
Drug: K‐rich/Na‐poor salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐rich/Na‐poor salt (2 g twice daily for 8 days)
Study: 3553479
Drug: Common salt
Normalized name: Common salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common salt (CS) (2 g twice daily for 8 days)
Study: 31287523
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine (n=922)
Study: 16870552
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (AT) at a dose of 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days.
Study: 14648922
Drug: Pro-hemostatic therapy
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-hemostatic therapy
Study: 11775646
Drug: Essaven gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essaven gel (EG)
Study: 16009169
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (twice a week for 5 weeks)
Study: 8496303
Drug: Daily injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injection of recombinant human GH (group 2)
Study: 8496303
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from continuous infusion to daily injections (group 1 during second period)
Study: 25190434
Drug: peg‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks (monotherapy)
Study: 25190434
Drug: peg‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks with ETV add-on (0.5 mg/daily starting at week 13)
Study: 25190434
Drug: peg‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks with ETV pretreatment (0.5 mg/daily for 24 weeks starting before peg‐IFN)
Study: 16848911
Drug: Early protocol
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early protocol with atropine at 10 and 20 mcg/kg/min of dobutamine (Groups A&B)
Study: 16848911
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol with atropine at 40 mcg/kg/min of dobutamine (Group C)
Study: 9248871
Drug: mianserin (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (10-60 mg/day)
Study: 9248871
Drug: haloperidol (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (2-6 mg/day)
Study: 21243928
Drug: Grass allergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergy immunotherapy tablet (Grazax), treatment lasted at least 8 weeks before the grass pollen season and continued until the season finished
Study: 19115441
Drug: Cognitive‐Behavioural Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioural Therapy (CBT) in addition to treatment as usual
Study: 11722966
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk (200 mL twice daily for 3 wk)
Study: 24442928
Drug: Peg‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2b monotherapy for 24 weeks (1.5 μg/kg/week)
Study: 24442928
Drug: Peg‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2b monotherapy for 12 weeks (1.5 μg/kg/week)
Study: 22291438
Drug: Vernakalant (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3.0 mg/kg infusion for 10 min)
Study: 22291438
Drug: Vernakalant (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (2.0 mg/kg infusion if AFL or AF persisted)
Study: 17937943
Drug: Buccal mucosa
Normalized name: Diazepam 5 MG Buccal mucosa Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mucosa dorsal onlay urethroplasty
Study: 10728182
Drug: Acupuncture (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (12 weekly sessions of minimal acupuncture and somatic moxibustion-acupuncture associated with auriculopuncture)
Study: 10728182
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 weekly sessions)
Study: 1769431
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cisapride
Study: 30569273
Drug: Teplizumab (anti-CD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teplizumab (anti-CD3 monoclonal antibody)
Study: 28538639
Drug: Emergency Preservation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency Preservation and Resuscitation (EPR) initiated via an intra‐aortic flush of a large volume of ice‐cold saline solution.
Study: 21685813
Drug: LEUPRO (leucine/protein/CHO/fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEUPRO (leucine/protein/CHO/fat supplement 7.5/20/89/22 g · h(‐1))
Study: 21685813
Drug: Control (isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isocaloric CHO/fat 119/22 g · h(‐1))
Study: 15180735
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) alone (2.2 mg/kg)
Study: 15180735
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) with olsalazine (0.5 g tid)
Study: 15180735
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (AZA + olsalazine)
Study: 11772451
Drug: Treatment schedules
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment schedules designed to take advantage of drug-induced changes in tumor tissue composition
Study: 28332984
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT) without the simultaneous integrated boost (SIB).
Study: 19155203
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
Study: 9883434
Drug: CTG (1.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTG (1.2% clindamycin phosphate, 0.025% tretinoin gel)
Study: 7104176
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg daily
Study: 21131142
Drug: Salvinorin A
Normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvinorin A (doses ranged from 0.375 μg/kg to 21 μg/kg)
Study: 9062345
Drug: Intravenous CGP
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CGP 51901 (3, 10, 30, and 100 mg)
Study: 8473790
Drug: rh‐SOD (10000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐SOD (10000 U/kg) administered through the aortic root into the coronary artery prior to reperfusion (group II)
Study: 31652073
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (0.45 mg/d)
Study: 31652073
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (50 µg/d)
Study: 25603890
Drug: Retinol 0.2%/LR2412
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol 0.2%/LR2412 2% cream
Study: 24189759
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 70 mg administered once-weekly for 12 months
Study: 24189759
Drug: Oral risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate 35 mg administered once-weekly for 12 months
Study: 19865538
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (150 mg/day for 42 days)
Study: 19865538
Drug: Quercetin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1, 10, 20 micromol/L) in RAW264.7 macrophages
Study: 17712236
Drug: High-dose atomoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atomoxetine (up to 3.0 mg/kg/day in study 1; up to 2.4 mg/kg/day in study 2)
Study: 17712236
Drug: Continued same-dose
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued same-dose atomoxetine
Study: 2679244
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-Dur tablets (200 mg theophylline anhydrous sustained-release) taken in the evening with food
Study: 2679244
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theo-Dur tablets (200 mg theophylline anhydrous sustained-release) taken in the evening without food
Study: 31504091
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with no choice
Study: 31237547
Drug: On-pump CABG
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-pump CABG with carbohydrate preoperative oral feeding
Study: 31237547
Drug: Off-pump CABG
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-pump CABG without carbohydrate preoperative oral feeding
Study: 31237547
Drug: Off-pump CABG
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-pump CABG with carbohydrate preoperative oral feeding
Study: 19374155
Drug: 0.2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL/kg ropivacaine 0.75% (group R)
Study: 19374155
Drug: 0.2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL/kg saline 0.9% (group F)
Study: 11465587
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) combined with physical therapy (PT)
Study: 7961547
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (type IA antiarrhythmics)
Study: 30005049
Drug: 20 μg teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 μg teriparatide (PTH)
Study: 28638192
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy (12 weeks, 3 times a week, 90 minutes per session)
Study: 28638192
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal medications only)
Study: 9684641
Drug: Allopurinol (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (8.5 mg/kg of body weight/day for 60 days)
Study: 9684641
Drug: Itraconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (6 mg/kg of body weight/day for 120 days)
Study: 341407
Drug: Salbutamol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (4 mg)
Study: 9278201
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg)
Study: 25225437
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg
Study: 23179200
Drug: Lifestyle counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle counseling + 30 g/day flaxseed supplementation (LCF)
Study: 12531794
Drug: CHOP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP with G-CSF
Study: 12531794
Drug: CHOP without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP without G-CSF
Study: 12531794
Drug: CNOP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNOP with G-CSF